-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 26 News On August 24, Kelun applied for the 4 types of imitation listing applications of terbutaline sulfate aerosol inhalation solution.
This product is the company's second inhaler to be marketed
.
According to data from Mi Nei.
com, in 2019, the sales scale of terbutaline sulfate nebulized inhalation solution in China's public medical institutions has exceeded 1.
3 billion yuan, and the current competition pattern is "1 import + 4 domestic production"
.
Figure 1: The situation of inhalants declared for listing by Kelun Source: CDE official website Figure 2: Sales of the two inhalants in the past three years (unit: 10,000 yuan) Source: Mi Nei.
com China's public medical institutions terminal competition pattern January 28 this year , Kelun submitted the first marketing application for inhalants, and the relevant acceptance number is currently under review and approval
.
Ipratropium bromide solution for inhalation is an anticholinergic drug, which has a strong bronchial smooth muscle relaxation effect, which can significantly improve the lung function and exercise tolerance of patients with chronic obstructive pulmonary disease (COPD) , and relieve the symptoms of dyspnea in patients.
Improving sleep and quality of life is one of the main drugs for the treatment of COPD
.
The original research product was developed by Boehringer Ingelheim and entered the domestic market in 2004.
It is a category A product in the National Medical Insurance Catalog
.
According to data from Minai.
com, in 2020, among the TOP20 products of terminal inhalants in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions), ipratropium bromide solution for inhalation ranks No.
Nine, the product has achieved sales of over 1 billion yuan in 2019.
In 2020, due to the epidemic affecting the frequency of patient visits, the overall sales scale has declined
.
Ipratropium bromide inhalation solution is incorporated into the fifth national Jicai, Shenzhen wife medicine, the four Trump Rui special medicine, Hebei Yikang Pharmaceutical Renhe Road, Wuhan, as well as to pharmaceutical science and technology four domestic pharmaceutical companies won the bid, It is expected that after the implementation, the market share of the original research drug company Boehringer Ingelheim will be quickly invaded
.
On August 24, Kelun’s second inhalation was declared for the market.
Terbutaline Sulfate Nebulized Inhalation Solution is an adrenaline β2 receptor agonist, which expands the bronchus by selectively exciting β2 receptors
.
Terbutaline can increase the mucociliary cleansing function that is reduced due to obstructive pulmonary disease, thereby accelerating the clearance of mucus secretions.
It is clinically suitable for bronchial asthma, chronic bronchitis, emphysema and other lung diseases accompanied by bronchospasm
.
AstraZeneca’s original products entered the domestic market in 2003 and are classified as Category B products in the National Medical Insurance Catalogue
.
According to data from Menet.
com, in 2020, terbutaline sulfate aerosol inhalation solution ranks sixth among the TOP20 products of terminal inhalants in China's public medical institutions in 2020.
It has become a product of over 1 billion since 2017.
It will be affected by the epidemic in 2020.
Sales fell
.
At present, the domestic pharmaceutical companies that have been approved for this product involve Shijiazhuang Siyao, Hebei Renheyikang Pharmaceutical, Suzhou Hongsen Pharmaceutical, and Sichuan Meidakang Huakang Pharmaceutical (not yet reviewed)
.
Table 1: Since 2021, Kelun and its subsidiaries have applied for listing and are expected to impact the first imitation products.
Source: Meinenet MED2.
0 Chinese drug review database.
According to data from Meinenet, Kelun and its subsidiaries have applied for listing since 2021.
There are 19 products, 18 of which are under review
.
Omega-3 fish oil medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection, eltroipopag ethanolamine tablets, escitalopram oxalate oral solution, enzalutamide soft capsule, citrate Seven products of fatib sustained-release tablets, sacubitril and valsartan sodium tablets and brimonidine timolol eye drops are expected to hit the first imitation
.
Source: CDE official website, the database
review data statistics of Mi Nei.
com as of August 25, please correct me if there are any errors or omissions
.
This product is the company's second inhaler to be marketed
.
According to data from Mi Nei.
com, in 2019, the sales scale of terbutaline sulfate nebulized inhalation solution in China's public medical institutions has exceeded 1.
3 billion yuan, and the current competition pattern is "1 import + 4 domestic production"
.
Figure 1: The situation of inhalants declared for listing by Kelun Source: CDE official website Figure 2: Sales of the two inhalants in the past three years (unit: 10,000 yuan) Source: Mi Nei.
com China's public medical institutions terminal competition pattern January 28 this year , Kelun submitted the first marketing application for inhalants, and the relevant acceptance number is currently under review and approval
.
Ipratropium bromide solution for inhalation is an anticholinergic drug, which has a strong bronchial smooth muscle relaxation effect, which can significantly improve the lung function and exercise tolerance of patients with chronic obstructive pulmonary disease (COPD) , and relieve the symptoms of dyspnea in patients.
Improving sleep and quality of life is one of the main drugs for the treatment of COPD
.
The original research product was developed by Boehringer Ingelheim and entered the domestic market in 2004.
It is a category A product in the National Medical Insurance Catalog
.
According to data from Minai.
com, in 2020, among the TOP20 products of terminal inhalants in China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions), ipratropium bromide solution for inhalation ranks No.
Nine, the product has achieved sales of over 1 billion yuan in 2019.
In 2020, due to the epidemic affecting the frequency of patient visits, the overall sales scale has declined
.
Ipratropium bromide inhalation solution is incorporated into the fifth national Jicai, Shenzhen wife medicine, the four Trump Rui special medicine, Hebei Yikang Pharmaceutical Renhe Road, Wuhan, as well as to pharmaceutical science and technology four domestic pharmaceutical companies won the bid, It is expected that after the implementation, the market share of the original research drug company Boehringer Ingelheim will be quickly invaded
.
On August 24, Kelun’s second inhalation was declared for the market.
Terbutaline Sulfate Nebulized Inhalation Solution is an adrenaline β2 receptor agonist, which expands the bronchus by selectively exciting β2 receptors
.
Terbutaline can increase the mucociliary cleansing function that is reduced due to obstructive pulmonary disease, thereby accelerating the clearance of mucus secretions.
It is clinically suitable for bronchial asthma, chronic bronchitis, emphysema and other lung diseases accompanied by bronchospasm
.
AstraZeneca’s original products entered the domestic market in 2003 and are classified as Category B products in the National Medical Insurance Catalogue
.
According to data from Menet.
com, in 2020, terbutaline sulfate aerosol inhalation solution ranks sixth among the TOP20 products of terminal inhalants in China's public medical institutions in 2020.
It has become a product of over 1 billion since 2017.
It will be affected by the epidemic in 2020.
Sales fell
.
At present, the domestic pharmaceutical companies that have been approved for this product involve Shijiazhuang Siyao, Hebei Renheyikang Pharmaceutical, Suzhou Hongsen Pharmaceutical, and Sichuan Meidakang Huakang Pharmaceutical (not yet reviewed)
.
Table 1: Since 2021, Kelun and its subsidiaries have applied for listing and are expected to impact the first imitation products.
Source: Meinenet MED2.
0 Chinese drug review database.
According to data from Meinenet, Kelun and its subsidiaries have applied for listing since 2021.
There are 19 products, 18 of which are under review
.
Omega-3 fish oil medium and long-chain fat emulsion/amino acid (16)/glucose (36%) injection, eltroipopag ethanolamine tablets, escitalopram oxalate oral solution, enzalutamide soft capsule, citrate Seven products of fatib sustained-release tablets, sacubitril and valsartan sodium tablets and brimonidine timolol eye drops are expected to hit the first imitation
.
Source: CDE official website, the database
review data statistics of Mi Nei.
com as of August 25, please correct me if there are any errors or omissions
.
